Nibel

Quick links to important sections

Nibel

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nibel

Property Description
Active Ingredient Nebivolol
Form Oral tablet
Pharmacological Class Beta-blocker (Third-generation)
Origin Synthetic compound
General Purpose Improves cardiac efficiency and circulation

What Type of Medicine is Nibel (Nebivolol)?

Nibel is a prescription-only medication that belongs to the Beta-blocker (beta-adrenergic blocking agent) pharmacological class. Its sole active ingredient is the synthetic compound Nebivolol, which is supplied as an oral tablet for administration by mouth. Nibel is clinically recognized for its selective action; it primarily targets the Beta-1 adrenergic receptors concentrated in the heart muscle.

This selective profile is a key differentiating factor, as it helps minimize effects on other receptors throughout the body. Furthermore, the active substance, Nebivolol, exists as a racemic mixture of two enantiomers, a characteristic chemical state of the active compound.

The Unique Composition and Action Profile

Nibel is consistently classified as a third-generation beta-blocker due to its unique compound structure and resulting dual mechanism of action. While its primary function is to modulate heart rhythm, Nebivolol also possesses pronounced vasodilating properties, meaning it helps widen and relax blood vessels.

This vasodilating effect is specifically mediated by the compound's ability to promote the release of Nitric Oxide (NO) from the lining of the blood vessels. This distinctive dual action—receptor blockade combined with NO-mediated vasodilation—differentiates Nebivolol from earlier generations of beta-blockers.

What is the General Purpose of Nibel?

The general therapeutic purpose of Nibel is to modulate and stabilize the overall dynamics of the cardiovascular system. By reducing the heart’s workload through a slower rate and simultaneously decreasing peripheral resistance via vessel relaxation, the medication is designed to improve cardiac efficiency. Its use is typically seen in the management of cardiovascular stress, where maintaining a balanced circulatory state is essential. The fundamental benefit is realized by ensuring the heart operates more smoothly.

What side effects are possible with Nibel?

Possible Side Effects and Safety Information

This section summarizes the adverse reactions and safety statements for Nibel (nebivolol) as officially documented in authoritative government regulatory sources.


Adverse Reaction Scope and Frequency

Official regulatory documents categorize adverse reactions based on their frequency and the body system affected:

  • Most Common Reactions: The most frequently documented undesirable effects reported in clinical trials include headache and fatigue.
  • System-Organ Classes: Documented effects span several body systems, including the Nervous System (e.g., dizziness), General Disorders, and the Cardiac System.

Serious Adverse Reactions and Restrictions

The regulatory profile highlights specific serious risks and strict limitations on use:

  • Serious Cardiac Events: Abruptly stopping this medicine, particularly in patients with existing coronary artery disease, carries an official regulatory risk of severe exacerbation of angina, myocardial infarction, and ventricular arrhythmias.
  • Contraindications: Nibel is formally prohibited (contraindicated) in patients with conditions such as severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, or severe hepatic impairment.

Population-Specific Safety Considerations

Safety notes for distinct patient groups as defined in official documents:

  • Pregnancy: Use during the second and third trimesters carries a risk of fetal or neonatal harm; discontinuation is generally recommended upon confirmation of pregnancy.
  • Organ Impairment: Caution and close monitoring are required for patients with renal impairment. The drug is formally contraindicated in those with severe hepatic impairment (Child-Pugh > B).
  • Discontinuation Warning: Treatment must not be stopped suddenly due to the documented risk of severe adverse reactions.

Connection to the Overall Safety Profile

The official safety information establishes a profile defined by strict absolute prohibitions related to pre-existing severe cardiovascular and hepatic conditions. It mandates that discontinuation must be gradual due to the documented risk of serious cardiac complications. The regulatory documents further specify safety modifications and cautions for distinct patient groups, such as those with organ impairment.

Overdose and Emergency Response

The official overdose profile for Nibel (Nebivolol) is defined by an exaggerated manifestation of its primary pharmacological effects, as documented in government regulatory labeling. These severe presentations necessitate immediate action.

Documented Overdose Manifestations

Overdose may present with critical cardiovascular signs, including profound severe bradycardia (slow heartbeat), marked hypotension (low blood pressure), and acute heart failure. Other officially documented clinical findings include heart block and bronchospasm (severe breathing difficulty).

Neurological effects such as confusion, convulsions, or coma may occur. A significant metabolic concern noted in official documents is the potential for severe or prolonged hypoglycemia (low blood sugar).

When to Seek Immediate Help

Government regulatory guidance mandates that you seek immediate medical attention upon any suspicion of overdose. This urgent action is required because severe outcomes, including cardiogenic shock and the risk of death, are documented risks associated with this type of overdose. You must contact a Poison Control Center or local emergency services immediately.

Supportive Management and Monitoring

Official labeling confirms that no specific antidote is available for Nebivolol overdose. Management, therefore, requires symptomatic and supportive treatment. This includes continuous monitoring of vital signs and ECG (Electrocardiogram) surveillance. Interventions described in official documents can include the use of intravenous fluids, vasopressors, and placement of a pacemaker in severe cases. Special attention is directed toward children and patients who are fasting, as they are at an increased risk for severe hypoglycemia.

Therapeutic Uses of Nibel

What Nibel Treats: Main Uses and Benefits

Nibel is commonly used in situations involving the management of high blood pressure (hypertension) and is applied in managing supportive care for stable chronic heart failure. Its primary therapeutic benefit is used to help with lowering systolic and diastolic pressure, which may assist with maintaining functional stability and reducing long-term cardiovascular burden.

The medication is relevant for easing symptoms related to these conditions, contributing to improved comfort during symptomatic periods. The medication plays a role in managing patterns of increased systemic vascular resistance and is particularly relevant for individuals with co-existing conditions like diabetes or generalized vascular disease.

“The medication is used across domains where additional symptomatic support is needed, particularly in situations where patients experience noticeable physiological strain.”

Quick Fact: Relief for Circulatory Pressure Overload The medication is commonly used to help manage symptoms associated with sustained high pressure and maintain a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Who Can and Cannot Use Nibel?

Nibel (Nebivolol) is a medication primarily prescribed for the management of essential hypertension (high blood pressure). It may also be used in the treatment of stable mild and moderate chronic heart failure in patients aged 70 years and older, as an addition to standard therapy.


Contraindications (Who Cannot Use Nibel)

Nibel is not suitable for everyone. It is contraindicated in patients with a known hypersensitivity to the active substance or any of the excipients. Additionally, it should not be used in individuals with:

  • Severe liver impairment or compromised liver function.
  • Acute heart failure or cardiac shock.
  • Sick sinus syndrome (unless a pacemaker is in place).
  • Second and third-degree atrioventricular (AV) block (without a pacemaker).
  • Severe bradycardia (very slow heart rate, below 60 beats per minute before starting treatment).
  • Severe peripheral arterial disease.
  • Hypotension (very low blood pressure).
  • Metabolic acidosis.
  • Asthma or history of bronchospasm (in the absence of proper control).

Special Populations

Population Use Consideration
Pregnancy Generally not recommended unless clearly necessary.
Breastfeeding Not recommended, as Nibel may pass into breast milk.
Children/Adolescents Not recommended due to a lack of data on safety and efficacy.
Elderly Used for chronic heart failure in patients 70 years; dose adjustments may be needed for hypertension.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nibel (Nebivolol) interaction patterns are defined by three core categories: metabolic interference, pharmacodynamic potentiation, and specific regulatory restrictions.

Metabolic and Exposure Interactions

Co-administration with CYP2D6 inhibitors, such as fluoxetine or paroxetine, leads to a pharmacokinetic interaction that increases nebivolol plasma levels and overall systemic exposure. This metabolic effect is also observed in individuals identified as CYP2D6 Poor Metabolizers, who exhibit substantially increased exposure due to reduced clearance. In cases of severe hepatic impairment, use of Nibel is formally contraindicated due to expected decreased metabolism and the resulting risk of accumulation.


Cardiovascular Potentiation

Interactions resulting in additive effects on the heart and blood vessels require caution. Co-administration with calcium channel blockers (Verapamil-type or Diltiazem-type) may lead to excessive reductions in heart rate and cardiac contractility, necessitating close monitoring of ECG and blood pressure. Similarly, Digitalis glycosides (e.g., Digoxin) can increase the risk of bradycardia through potentiated effects on AV conduction. Certain catecholamine-depleting drugs may also produce an excessive reduction of sympathetic activity.


Specific Restrictions and Food

Drug combinations formally classified as contraindicated by some regulatory labels include Floctafenine and Sultopride due to high-risk adverse potential. The drug's absorption is not affected by food, and no mandatory timing rule is necessary; however, some documents note that antacids may be taken between meals if Nibel is taken with the meal.

Mechanism of Action

How Nibel Works

Nibel operates through a dual mechanism that targets both the heart and the blood vessels and influences physiological processes. This targeted action influences core mechanisms regulating cardiovascular function.


Selective beta1 Receptor Blockade in the Heart

This domain involves the drug's primary action: binding to and acting as an antagonist of beta1-adrenergic receptors, which are mainly located in the heart. By preventing catecholamines like norepinephrine from binding here, the mechanism limits sympathetic stimulation, reducing the heart's rate and force of contraction. This results in reduced myocardial workload and oxygen demand.


Modulation of Endothelial Function

This secondary domain involves the drug's effect on the lining of blood vessels (the endothelium). The mechanism enhances the release of the signaling molecule nitric oxide (NO) from these cells. Nitric oxide then acts on vascular smooth muscle to cause relaxation. This action reduces the peripheral vascular resistance, contributing to the reduction of arterial blood pressure.

Dosage and Administration Information

Nibel is administered exclusively by the oral route as a tablet and is intended for once-daily use, preferably taken at the same time each day. The tablets, which are available in strengths from 2.5 mg up to 20 mg, may be taken with or without food.

Dosing Regimens and Titration

Treatment follows a gradual titration schedule. For the management of hypertension, the initial dose is typically 5 mg once daily, and the dose may be increased at intervals of approximately two weeks to a maximum recommended dose of 40 mg. For the management of stable chronic heart failure, regimens often begin at a very low dose of 1.25 mg, which is incrementally raised every one to two weeks up to a maximum of 10 mg, requiring close medical supervision during this initial phase.

Usage Constraints and Adjustments

A lower initial daily dose of 2.5 mg is necessary for individuals with severe renal impairment or moderate hepatic impairment. Use is not supported for pediatric patients. As a principle of long-term use, Nibel should never be stopped abruptly; if discontinuation is necessary, the dose must be gradually tapered to manage the procedural constraint of withdrawal.

Recent Clinical Evidence

Evidence for Use in Managing High Blood Pressure (Hypertension)

Research exploring the use of Nibel in conditions such as high blood pressure has primarily relied on short-term, randomized, double-blind, placebo-controlled trials (RCTs). These studies focused on objective, short-term measures, chiefly examining the change in seated systolic and diastolic blood pressure (SBP/DBP) over periods typically lasting a few months. Outcomes monitoring physiological strain or stress were the central focus of these studies. Trials reported measurements of change in blood pressure readings that differed from the placebo groups. Research also examined genetic factors, specifically related to the enzyme CYP2D6, which were associated with differences in the amount of active drug reported in the body.


Evidence for Use in Supportive Care for Stable Chronic Heart Failure

Research investigating Nibel was evaluated in the context of stable chronic heart failure using large-scale, long-term, multinational, randomized outcome trials. These studies monitored outcomes related to all-cause mortality and hospital admissions due to cardiovascular reasons over extended periods. The pivotal research in this area involved studies observing responses primarily in an older adult population (70 years). Studies report how functional measures, such as patient capacity, evolved in the observed populations.


Long-Term Studies and Research Gaps

Long-term studies for high blood pressure are not fully established by dedicated Nibel-specific outcome trials; findings mainly apply to short-term blood pressure measurements. The majority of the mortality and morbidity evidence is concentrated in the older adult chronic heart failure cohort, meaning data for younger individuals with the condition are less extensive. Comparative evidence is sometimes lacking to definitively show if Nibel's unique action was associated with a difference in long-term survival for all patient groups.

Frequently Asked Questions (FAQ)

Common questions about Nibel (FAQ)

Q: Does Nibel interact with common over-the-counter pain relievers?

A: Official information indicates that non-steroidal anti-inflammatory drugs (NSAIDs), which include common over-the-counter pain relievers, may potentially reduce the blood pressure-lowering effect of beta-blockers when taken long-term (more than one week). It is important for individuals to discuss all medications they are taking, including OTC pain relievers, with a healthcare professional.

Q: What happens if I accidentally skip a dose of Nibel?

A: If a dose is missed, general guidance for this class of medicine suggests skipping the missed dose and taking the next dose at the usual time. It is advised not to take two doses at once to compensate. If doses are frequently missed, discussing a consistent schedule with a healthcare professional may be helpful.

Q: Can Nibel interact with herbal supplements like St. John's Wort?

A: Nibel is metabolized (processed by the body) by an enzyme called CYP2D6. While St. John's Wort is not always explicitly listed in product documents, this herbal supplement is known to affect certain enzyme systems, which could potentially alter the concentration of Nibel in the blood. For safety, caution is advised when combining medications with herbal supplements.

Q: What should I do if I experience an unusual rash after starting Nibel?

A: The adverse event list includes rash as a possible side effect. If an unusual rash develops, official guidance advises contacting a healthcare professional or pharmacist for assessment. Immediate medical attention is necessary if the rash is part of a serious allergic reaction, such as swelling or difficulty breathing.

Q: What are the signs of a serious allergic reaction to Nibel?

A: Signs of a severe allergic reaction to Nibel, which require immediate emergency medical attention, may include swelling of the face, lips, tongue, or throat. Difficult breathing or the appearance of hives are also recognized as potential signs of a serious reaction.

Q: Is Nibel a first-line treatment for its indication?

A: Nibel is approved for the treatment of high blood pressure and may be used either alone or in combination with other blood pressure-lowering agents. Its use is part of a comprehensive strategy consistent with management guidelines for cardiovascular health.

Q: Can Nibel be crushed or split if swallowing is difficult?

A: Some strengths of the Nibel tablet are manufactured with a scoring or debossed line, indicating that they may be divided into smaller parts. This may be done to achieve specific low dosing or aid easier administration. Patients can confirm with their pharmacist whether their specific tablet strength is designed to be divided.

Q: Can Nibel cause weight gain or weight loss?

A: While regulatory documents do not list general changes in body weight as a common side effect, they do note that rapid weight gain is a serious side effect that should be reported to a healthcare professional. This is especially relevant if it is associated with symptoms like shortness of breath or swelling.

Q: Can Nibel affect my ability to drive or operate machinery?

A: Official information advises caution when performing tasks like driving or operating machinery. Adverse effects such as lightheadedness, dizziness, or syncope (fainting) may occur and could potentially impair an individual's ability to concentrate and react safely.

Q: What foods or supplements should be avoided when taking Nibel?

A: While Nibel may generally be taken with or without food, some regulatory documents advise caution regarding grapefruit juice. Grapefruit juice can interfere with the body's metabolism of the drug, which may increase the level of Nibel in the blood and potentially enhance the blood pressure-lowering effect.

Q: Is Nibel used for conditions other than high blood pressure?

A: Yes. In addition to treating high blood pressure, Nibel is also officially indicated as a supplemental treatment for stable mild and moderate chronic heart failure. This indication is typically limited to elderly patients aged 70 years and older, as an addition to standard therapy.

Q: Can Nibel be used by individuals with diabetes?

A: Nibel can be used by individuals with diabetes, but official warnings state that caution is necessary. This is because the medication's beta-blocking effects may mask certain physical symptoms of low blood sugar (hypoglycaemia), specifically the fast heart rate that usually occurs.

Q: Is it normal to have cold hands or feet while taking Nibel?

A: Official product information lists a cold feeling or numbness in the hands and feet as a possible side effect of Nibel. This is related to the drug's known mechanism of action on peripheral circulation.

Q: Can Nibel affect sexual function?

A: Erectile dysfunction is listed in official documents as an uncommon adverse reaction reported during clinical trials for Nibel.

Q: How long does it take for Nibel to reach its maximum effect?

A: According to official documentation, the blood pressure-lowering effect of Nibel is usually noticeable after one to two weeks of continuous treatment. However, the optimal and maximum therapeutic effect may not be fully established until approximately four weeks after starting the medication.

Q: Why is it important to take Nibel at the same time every day?

A: Nibel is prescribed for once-daily use. The key regulatory recommendation is to take the dose consistently at the same time each day to maintain stable and predictable drug levels in the bloodstream, helping to manage blood pressure effectively over a 24-hour period.

Q: What are the restrictions on alcohol consumption while taking Nibel?

A: Official sources advise that caution should be exercised regarding alcohol consumption while taking Nibel. Alcohol can potentially enhance the blood pressure-lowering effects of the drug, which may increase the risk of experiencing lightheadedness or dizziness.

Q: What kind of monitoring (blood tests, etc.) is needed while on Nibel?

A: Close medical monitoring is required, especially during the initial phases of treatment for heart failure. Official documents also indicate that patients with reduced kidney or liver function will require specific, close monitoring and likely necessitate a dose adjustment.

Q: Does Nibel cause coughing like some other blood pressure medicines?

A: Yes, official information lists coughing as a common side effect reported in clinical trials. Other common reports included upper respiratory tract issues like the common cold (nasopharyngitis) and bronchitis.

Q: Are there specific patient groups that respond better to Nibel?

A: Clinical studies for stable chronic heart failure focused primarily on an older adult population, aged 70 years and older, showing evidence in this cohort. For the treatment of high blood pressure, efficacy is generally reported to be similar across various populations, but benefits may be greater in patients at higher cardiovascular risk.

Q: Why do some users report a headache when starting Nibel?

A: Headache is listed in official regulatory documents as one of the most frequently documented undesirable effects reported in clinical trials. It is commonly classified as a very common or common reaction when initiating treatment.

Q: Is Nibel considered a 'selective' or 'non-selective' beta-blocker?

A: Nibel is officially classified as a selective beta-1 adrenergic receptor blocker. This means its primary action targets the specific beta-1 receptors that are mostly concentrated in the heart muscle, helping to reduce its workload.

Q: Can Nibel make existing depression or anxiety worse?

A: Official safety documents list both depression and anxiety as uncommon reported adverse reactions. Individuals with a history of these conditions should discuss them with a healthcare provider.

Q: Is it better to take Nibel in the morning or at night?

A: Nibel is prescribed as a once-daily tablet. The patient may take it at any time of the day. The key regulatory recommendation is to take the dose consistently at the same time each day to maintain steady blood levels.

Q: Why is grapefruit juice often mentioned as interacting with blood pressure drugs like Nibel?

A: Some drug documents for Nibel-containing products advise caution or avoidance of grapefruit juice. This is due to the potential for grapefruit to interfere with the body's metabolism of Nibel, which could increase the drug concentration in the blood and lead to an enhanced blood pressure-lowering effect.

Q: Can Nibel affect sleep patterns or cause insomnia?

A: Yes, official regulatory documents list insomnia (difficulty falling asleep or staying asleep) as an uncommon adverse reaction reported during clinical trials for Nibel.

Q: Are there generic versions of Nibel available?

A: Yes, the active ingredient in Nibel is Nebivolol. Regulatory bodies in various countries, including the US, have approved generic versions of Nebivolol tablets, making the drug available under different manufacturers' names.

How should Nibel be stored and disposed of?

Nibel (nebivolol) tablets must be stored according to regulatory specifications to maintain product integrity and safety.

Official Storage Requirements

Requirement Description (As per Regulatory Labeling)
Temperature Store at controlled room temperature, typically between 15 C to 30 C (59 F to 86 F).
Protection Protect from light and moisture. Keep from freezing and excessive heat.
Container Keep the tablets in their original, tightly closed container until use.
Stability Do not use this medicine after the expiry date (EXP) stated on the package.
Child Safety Keep this medicine out of the sight and reach of children.

Official Disposal Rules

Discarding unused or expired Nibel must adhere to specific instructions to protect the environment and public health. Regulatory documents mandate that the product must not be thrown away via household garbage or flushed down the sink/toilet (wastewater).

Disposal must be completed in accordance with local pharmaceutical waste regulations (e.g., drug take-back programs) or by following the instructions provided by a pharmacist or healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nibel found in:

A-Z Index: